Key facts
- iNEX Innovate’s last known valuation is $27.3M.
- It has raised $13.6M; the latest was Later Stage VC ($1.6M) in Oct 2024.
- Notable investors include SEEDS Capital, Genting, National University of Singapore, Severn River Capital Management.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for iNEX Innovate
- ·The full record, as it builds
Funding rounds
No funding rounds for iNEX Innovate are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iNEX Innovate
Developer of molecular diagnostic technologies designed to improve women's and fetal health through early detection and clinical innovation. The company platform offers proprietary tests for conditions such as ovarian, breast, and endometrial cancers, along with patented fetal cell isolation methods, provides laboratory services and research-driven diagnostic platforms supported by intellectual property development and global partnerships, enabling healthcare providers and academic institutions to access advanced diagnostic capabilities while enhancing patient outcomes, clinical accuracy, and equitable access to women's health diagnostics.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2006
- Employees
- 53
- Website
- inex.sg/
- Ownership
- Privately Held (backing)
iNEX Innovate doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iNEX Innovate shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iNEX Innovate in its N-PORT filings yet. We sweep new filings monthly.